Straits Times Index
3,363.52 +24.95 (+0.75%) Nikkei
40,074.69 +443.63 (+1.12%) Hang Seng
17,762.05 +43.44 (+0.25%) FTSE 100
8,166.76 0.00 (0.00%) Bitcoin USD
62,623.17 -676.76 (-1.07%) CMC Crypto 200
1,347.01 +2.50 (+0.19%)
CDNA Aug 2024 10.000 call
| Previous close | 3.9000 |
| Open | 3.9000 |
| Bid | 4.2000 |
| Ask | 7.2000 |
| Strike | 10.00 |
| Expiry date | 2024-08-16 |
| Day's range | 3.9000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 31 |
Business WireLandmark Independent Publication in Nature Medicine Validates CareDx AlloView AI-Enabled Risk Prediction Model and Demonstrates AlloSure Kidney Detects Subclinical Rejection in Stable Patients
BRISBANE, Calif., June 03, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and of
Business WireAI Integration and Real-World Utility of CareDx Portfolio Highlighted in New Data at the 2024 American Transplant Congress
BRISBANE, Calif., May 30, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new data to be presented at the 2024 American Transplant Congress (ATC) being held June 1-5 in Philadelphia.
Business WireCareDx Reiterates Position that it Does Not Infringe the ‘544 Patent, Injunction Motion is Irrelevant
BRISBANE, Calif., May 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.’s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent).
